How does the body respond to humira biosimilar injections?

How does the body respond to Humira biosimilar injections?

The introduction of biosimilars, similar versions of biologic medications, has raised questions about their safety and efficacy compared to the original products. Humira, a widely used biologic medication, has several biosimilars in development [1] and recently approved by regulatory agencies.

What happens when a Humira biosimilar is administered?

When a Humira biosimilar is injected into the body, it works similarly to the original Humira, targeting tumor necrosis factor-alpha (TNF-alpha), a substance in the body associated with autoimmune diseases. By binding to TNF-alpha, the biosimilar reduces inflammation and other symptoms of conditions like rheumatoid arthritis, psoriasis, and Crohn's disease [2].

How does the body differentiate a biosimilar from the original Humira?

The body recognizes Humira and its biosimilars as foreign substances, triggering an immune response. This response is generally mild and temporary, as the immune system adapts to the presence of the biologic. The immune response may include the production of antibodies against the biosimilar, but these are typically not as aggressive as those against the original biologic [3].

Are there any differences in side effects between Humira and its biosimilars?

Clinical trials have shown that Humira biosimilars have a similar safety profile to the original Humira. The most common side effects include injection site reactions, headaches, and respiratory infections. However, the incidence of rare and severe side effects, such as anaphylaxis and malignancy, may vary between the original and biosimilar versions [4].

When can patients expect the patent to expire for original Humira?

AbbVie, the manufacturer of Humira, has been actively defending its patent against generic and biosimilar challengers. Despite the recent approval of several Humira biosimilars, the patent for original Humira is still in place. However, the patent expiration date for Humira in the United States is April 2023 for certain indications [5].

Sources:

[1] https://www.drugpatentwatch.com/drugs/humira-100mg-ml-injection-solution
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441330/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461110/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344449/
[5] https://www.drugpatentwatch.com/patents/humira-100mg-ml-injection-solution